IRCT20231010059674N1 IRCT 2024-12-12 national university of medical sciences Comparative analysis of efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis in tertiary care hospital none Comparative analysis of efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis in tertiary care hospital 2024-05-01 anticipated 60 Complete https://irct.ir/trial/73203 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: patients will be followed for 12 weeks with monthly followup, Randomization description: Coding will be done by the dermatologist.Patients will be randomised into two groups by lottery method.The code will be chosen by the patient, Blinding description: In this single blind study the researcher (outcome assessor )will be blinded. The treating dermatologist and the patients will be aware of the treatment provided with the label of " intention to treat single blind study". 4 psoriasis. Intervention 1: Control group:oral route is considered gold standard treatment in severe psoriasis so it will be considered as control group. Patients will receive 10-25 mg /week oral Methotrexate for 3 months with weekly followup.Monthly followup will be done for next 3 months to check for relapse. Intervention 2: Intervention group: Patients in this group will receive methotrexate in a dose of 10-25 mg weekly by subcutaneous route and will be followed up weekly for 3 months. Afterwards they will be followed for relapse by monthly visits for next 3 months. Yes - There is a plan to make this available What will be shared: Comparative Analysis of Efficacy and Safety of Oral Versus Subcutaneous Methotrexate in Severe Psoriasis in Tertiary Care Hospital When: 12 months To whom: academic Conditions: article Where to obtain: google scholar How to obtain: internet Comments: no